β³ Fetching live dividend data...
Home βΊ Calculator βΊ INCPF Dividend Calculator 2026
InnoCare Pharma Limited Β· OTC
Price: $1.60 Β· Annual div: None Β· Frequency: β Β· Payout ratio: N/A Β· Ex-div: β
INCPF is not a dividend-focused stock
INCPF pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
InnoCare Pharma Limited (INCPF) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
InnoCare Pharma Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments, primarily targeting cancer and autoimmune disorders. A key product in their portfolio is Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This therapy targets various relapsed or refractory blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma (MCD subtype), central nervous system lymphoma, and is also being explored in combination with MIL-62. Furthermore, Orelabrutinib is under investigation for a range of autoimmune conditions such as systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company's broader pipeline features several investigational candidates in various clinical trial stages. For example, ICP-192, a pan-FGFR inhibitor, is currently in Phase I/II trials for solid tumors like cholangiocarcinoma and head and neck cancer. Compounds in Phase I clinical trials include ICP-723, a pan-TRK inhibitor addressing cancers with neurotrophic tyrosine receptor kinase fusions; ICP-332, a novel tyrosine kinase 2 (TYK2) inhibitor for autoimmune diseases; and ICP-B02, a bispecific antibody targeting lymphoma. Further preclinical and early-stage assets encompass ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver, renal cell, colorectal, and other solid tumors; ICP-488 for autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for various cancers; and ICP-248 and ICP-490, both focusing on hematological conditions, with ICP-490 also extending to autoimmune diseases. Additionally, InnoCare offers Tafasitamab (marketed as ICP-B04), indicated for the treatment of diffuse large B-cell lymphoma and other hematological malignancies. Established in 2015, InnoCare Pharma Limited maintains its headquarters in Beijing, China.
No. InnoCare Pharma Limited (INCPF) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. INCPF has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data Β· open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open INCPF position with:
Real after-tax yield depends on where you live and how you hold INCPF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| π©πͺ DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| π«π· FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
INCPF pays quarterly β 4 times per year. Ex-div: β.
How INCPF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for INCPF sourced from FMP /financial-growth endpoint β real data, not estimates.
Compare INCPF with peers: INCPF vs AKBLF Β· INCPF vs CAMRF Β· INCPF vs CLCGY
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the INCPF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
InnoCare Pharma Limited (INCPF) is currently trading at $1.60, trading near its 52-week low. It does not currently pay a regular dividend.
InnoCare Pharma Limited (INCPF) is a healthcare stock trading at $1.60. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only β not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
News aggregated from public sources via Finnhub & RSS. For informational purposes only.
β±οΈ Takes 30 seconds Β· No signup Β· Free forever